

ASSIGNMENT

WHEREAS, PHARMACIA & UPJOHN AB, a Swedish Aktiebolag, having a place of business at Lindhagensgatan 133, S11287, Stockholm, Sweden (hereinafter, "ASSIGNOR") has adopted the trademarks identified in Schedule A and Schedule B annexed hereto for use in the United States; and

WHEREAS, ASSIGNOR owns the trademark registrations identified in Schedule A annexed hereto and the trademark applications in Schedule B annexes hereto; and

WHEREAS, FRESENIUS KABI AB, a Swedish Aktiebolag, located and doing business at SE-751, 74 Uppsala, Sweden, (hereinafter, "ASSIGNEE") is desirous of acquiring said trademarks and said federal trademark registrations and federal trademark applications.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, said ASSIGNOR does hereby assign unto the said ASSIGNEE all rights, title and interest in and to the said mark in the United States, together with that portion of the business connected with the use and symbolized by the marks and any and all goodwill of the business symbolized by the marks, and the above-identified trademark registrations and applications.

Date: June 24, 1999

PHARMACIA & UPJOHN AB

By: 

Name: Fredrik Berg Harald Alm

Title: *VP, ASS. GEN. COUNSEL*

VP, Finance, Accounting & reporting, Sweden

50100 v 1

TRADEMARK
REEL: 002270 FRAME: 0039

U/18/99

SCHEDULE A

<u>Trademark</u>	<u>Reg. No.</u>	<u>Registration Date</u>
INTRALIPID	762,641	January 7, 1964
KABI	915,350	June 22, 1971
NOVAMINE	1,640,184	April 9, 1991
OXALERT	2,172,356	July 14, 1998
VACUMAT	1,377,885	January 14, 1986

* * *

SCHEDULE B

<u>Trademark</u>	<u>Serial No.</u>	<u>Filing Date</u>
GLAMIN	75/344,687	August 21, 1997
PHARMAMIX	75/282,943	April 28, 1997
SOLUVIT	74/656,599	April 5, 1995
STRUCTOLIPID	75/596,951	November 30, 1998
VITALIPID	75/096,582	April 30, 1996
VITAPED	75/442,549	March 2, 1998

* * *

LHM